Science Talk
With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow them to tell some of the stories behind the science. We try to put our discoveries in a wider scientific context, and give an idea of how our science is actually done. We also give you the view from the ICR of important developments in the wider world of cancer research.
Targeted treatments, big data and the pros and cons of having your genome sequenced
The ICR’s Professor Nazneen Rahman took part in an international debate on genomics – and is keen to hear your views on knowing your sequence
3D assays, genetic tests going mainstream and new ‘epigenetic’ drugs – ICR researchers gaze into their crystal balls
We asked some of our top researchers to take a look forward to what they expect for 2015. Here are their predictions about the upcoming year...
Huge team effort on REF is rewarded by a fantastic result and memorable week
It was an enormous undertaking from our research and support staff to submit to the REF process – Dr Barbara Pittam reflects on a memorable week for The Institute of Cancer Research.
Why patients need to be involved in using data to transform cancer care
This year’s Britain Against Cancer conference brought together MPs, policy makers, researchers, clinicians and patients to discuss cancer policy.
Looks can be deceiving: high grade glioma in children and adults
Two diseases that look the same might be hiding different genetic mutations.
How three generations of precision medicine are transforming lung cancer
Lung cancer is the biggest killer in cancer, but treatments targeting specific mutations are now offering patients a lifeline, and displaying the power of precision medicine.
Picking out the year's 10 most exciting discoveries in cancer research
ICR research takes a step closer to patients as olaparib is assessed for NHS
“Three solutions to cancer’s drug resistance” – Professor Paul Workman visits China
Professor Paul Workman, Interim Chief Executive of The Institute of Cancer Research, London, took a global perspective on cancer in a high-profile talk this week.
Day three at the UK’s biggest cancer conference: clinical trials, metabolomics, and targeted therapies
Finding the right target for liver cancer treatment
Where are we going with patient care, genomics and targeted therapies?
Buzz as UK’s biggest cancer conference gets underway
Goodbye flat biology
ICR researchers to present on topics from evolution to imaging at UK’s biggest cancer conference
Smoke signals – tracking cancer through the metabolic signatures it gives off
Cancer cells display many different characteristics to normal tissue. Research from a new ICR team leader could use cancer’s unique metabolism to diagnose and treat the disease.
How to beat cancer at the evolution game
The evolution of cancer cells can cause tumours to become resistant to treatment – which is why we need to get smart to fight them effectively.
Our international mix of PhD students learn at the front line of cancer research
The ICR is currently recruiting for a range of fully funded four-year PhD studentships. Read about how our PhD students contribute to our cutting-edge research and why the ICR is a great place to study.
European Commission misses a chance to open a pipeline of cancer drugs to children
The ICR has been campaigning for changes to the EU Paediatric Regulation, which we believe could make a real difference to the number of new cancer drugs which enter clinical trials in children. Here we look at a missed opportunity for change.
NICE pauses abiraterone decision for further price discussions
After first deciding to block earlier use of prostate cancer drug abiraterone, NICE has now suspended its appraisal, allowing more discussion on the price. Here Dr Eva Sharpe summarises what is new.